These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12720497)

  • 21. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S;
    Lancet; 2002 Mar; 359(9311):1004-10. PubMed ID: 11937179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
    Anis AH; Sun H; Singh S; Woolcott J; Nosyk B; Brisson M
    Pharmacoeconomics; 2006; 24(4):387-400. PubMed ID: 16605284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
    Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 28. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
    Geriatrics; 2002 May; 57(5):63-4. PubMed ID: 12040595
    [No Abstract]   [Full Text] [Related]  

  • 33. [LIFE study proves preventive action. With losartan to do even more against stroke].
    Baumgart P
    MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
    [No Abstract]   [Full Text] [Related]  

  • 34. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 2000 Aug; 13(8):899-906. PubMed ID: 10950398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    Einecke D
    MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
    [No Abstract]   [Full Text] [Related]  

  • 38. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
    Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
    J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.